Patents by Inventor Gagan Kukreja
Gagan Kukreja has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230089381Abstract: The present invention discloses a fused heterocyclic compound of formula (I), wherein, Q, R1, R2, n, m and Y are as defined in the detailed description. The present invention further discloses methods for their preparation and use of the compounds of formula (I) as a pest control agent.Type: ApplicationFiled: February 17, 2021Publication date: March 23, 2023Applicant: PI INDUSTRIES LTD.Inventors: Gagan KUKREJA, Suresh Kumar SUTHAR, Viraj SINGH, Narasimha Murthy CHEEMALA, Sandeep Ashok KAPE, Rohit SAXENA, Chandan MAITY, Vishwanath GADE, Ravikumar Suryanarayana SARAGUR, Alexander G.M. KLAUSENER
-
Publication number: 20220251094Abstract: The present invention discloses a fused heterocyclic compound of formula (I), wherein, R1, Y, Q, A, G, m and E are as defined in the detailed description. The present invention further discloses methods for their preparation and use of the compounds of formula (I) as a pest control agent.Type: ApplicationFiled: June 12, 2020Publication date: August 11, 2022Applicant: PI INDUSTRIES LTD.Inventors: Gagan KUKREJA, Vikas KUMAR, Lalit Kumar JENA, Jeevan Singh VERMA, Rohit SAXENA, Sunil Kumar MANDAL, Vishwanath GADE, Kiran K C, Ravikumar Suryanarayana SARAGUR, Alexander G.M. KLAUSENER
-
Publication number: 20210052556Abstract: Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.Type: ApplicationFiled: March 26, 2020Publication date: February 25, 2021Inventors: Gagan Kukreja, Nageswara Rao Irlapati, Arun Rangnath Jagdale, Gokul Keruji Deshmukh, Vinod Popatrao Vyavahare, Kiran Chandrashekhar Kulkarni, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20190275012Abstract: Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.Type: ApplicationFiled: July 28, 2017Publication date: September 12, 2019Inventors: Gagan Kukreja, Nageswara Rao Irlapati, Arun Rangnath Jagdale, Gokul Keruji Deshmukh, Vinod Popatrao Vyavahare, Kiran Chandrashekhar Kulkarni, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20190160045Abstract: Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.Type: ApplicationFiled: July 28, 2017Publication date: May 30, 2019Inventors: Gagan Kukreja, Nageswara Rao Irlapati, Arun Rangnath Jagdale, Gokul Keruji Deshmukh, Vinod Popatrao Vyavahare, Kiran Chandrashekhar Kulkarni, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9359367Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.Type: GrantFiled: July 9, 2013Date of Patent: June 7, 2016Assignee: Lupin LimitedInventors: Gourhari Jana, Sanjay Pralhad Kurhade, Arun Rangnath Jagdale, Gagan Kukreja, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20150152118Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.Type: ApplicationFiled: July 9, 2013Publication date: June 4, 2015Applicant: LUPIN LIMITEDInventors: Gourhari Jana, Sanjay Pralhad Kurhade, Arun Rangnath Jagdale, Gagan Kukreja, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 7825147Abstract: The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.Type: GrantFiled: August 30, 2004Date of Patent: November 2, 2010Assignee: Ranbaxy Laboratories LimitedInventors: Venkata P. Palle, Sarala Balachandran, Mohammad Salman, Gagan Kukreja, Nidhi Gupta, Abhijit Ray, Sunanda G. Dastidar
-
Publication number: 20100093726Abstract: The present invention relates to clotrimazole/quinoline hybrids useful as active ingredients of anti-malaria drugs. The compounds show a remarkable in vitro biological activity especially against the chloroquine-resistant Plasmodium falciparum strains and in vivo activity against P. berghei.Type: ApplicationFiled: February 18, 2008Publication date: April 15, 2010Applicant: Giuseppe CAMPIANIInventors: Giuseppe Campiani, Sandra Gemma, Caterina Fattorusso, Gagan Kukreja, Bhupendra Prasad Joshi, Stefania Butini, Marco Persico, Salvator Sanna Coccone, Matteo Bernetti
-
Publication number: 20080280926Abstract: The present invention relates to purine derivatives, which can be used as selective phosphodiesterase (PDE) type IV inhibitors. Compounds disclosed herein can be useful in the treatment of asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Also provided are processes for the preparation of disclosed compounds, pharmaceutical composition containing the disclosed compounds and their use as selective phosphodiesterase (PDE) type IV inhibitors.Type: ApplicationFiled: December 16, 2004Publication date: November 13, 2008Inventors: Venkata P. Palle, Sarala Balachandran, Mohammad Salman, Gagan Kukreja, Lalit Kumar Baregama, Abhijit Ray, Sunanda Ghosh Dastidar
-
Publication number: 20070259874Abstract: The present invention relates to isoxazoline derivatives and their analogues, which can be used as phosphodiesterase (PDE) type IV selective inhibitors. Compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases, especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and their use as PDE type IV selective inhibitors, are provided.Type: ApplicationFiled: November 26, 2004Publication date: November 8, 2007Inventors: Venkata Palle, Sarala Balachandran, Nidhi Gupta, Gagan Kukreja, Manoj Khera, Lalit Baregama, Raghuramaiah Mandadapu, Abhijit Ray, Sunanda Dastidar
-
Publication number: 20050075383Abstract: The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.Type: ApplicationFiled: August 30, 2004Publication date: April 7, 2005Inventors: Venkata Palle, Sarala Balachandran, Mohammad Salman, Gagan Kukreja, Nidhi Gupta, Abhijit Ray, Sunanda Dastidar